NASS is a multidisciplinary medical organization dedicated to improving spine care. NASS is the largest spine society in the world with over 9,000 members. NASS has issued a formal coverage recommendation for minimally invasive SI joint fusion titled "Percutaneous Sacroiliac Joint Fusion.” This evidence-based coverage policy states "the Coverage Committee recommends coverage for percutaneous SI joint fusion when the criteria [outlined] are met." This recommendation for coverage of minimally invasive SI joint fusion as a treatment option for those patients who satisfy the diagnostic criteria is a major milestone for spine focused health care practitioners. This broad group of spine specialists (NASS) now endorses the diagnosis and treatment of SI joint disorders. The NASS coverage recommendation further validates the existing minimally invasive SI joint fusion coverage recommendation from ISASS (International Society for the Advancement of Spine Surgery) and should help to further expand insurance coverage for the iFuse procedure throughout the US.
The criteria in the NASS coverage recommendation have been established in an effort to ensure that patients are appropriately diagnosed and that they receive appropriate non-surgical treatment prior to percutaneous / minimally invasive sacroiliac joint fusion. Appropriate diagnosis includes history, physical examination and appropriate response to two diagnostic injections. In addition, other potential sources of pain such as the lumbar spine and hip should be ruled out. Non-surgical treatment should include a therapeutic SI-joint injection. MIS SI joint fusion should not be considered prior to 6 months after onset of SI joint symptoms.